These insights establish TLKs as pharmacologically exploitable targets in ALT-driven tumors and chromosomally unstable cancers, while providing mechanistic context for understanding how the circ-MBOAT2 coordinates immune evasion in NSCLC pathogenesis through TLK1-dependent regulation [40]. Here, TLK1 is linked to cancer.